These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29435178)

  • 1. Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer.
    Awasthi N; Monahan S; Stefaniak A; Schwarz MA; Schwarz RE
    Oncotarget; 2018 Jan; 9(4):5274-5286. PubMed ID: 29435178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
    Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
    Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.
    Awasthi N; Scire E; Monahan S; Grojean M; Zhang E; Schwarz MA; Schwarz RE
    Oncotarget; 2016 Jul; 7(30):46988-47001. PubMed ID: 27127884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer.
    Awasthi N; Mikels-Vigdal AJ; Stefanutti E; Schwarz MA; Monahan S; Smith V; Schwarz RE
    J Cell Mol Med; 2019 Jun; 23(6):3878-3887. PubMed ID: 30941918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.
    Awasthi N; Zhang C; Schwarz AM; Hinz S; Schwarz MA; Schwarz RE
    Mol Cancer Ther; 2014 May; 13(5):1032-43. PubMed ID: 24608575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models.
    Crawford K; Bontrager E; Schwarz MA; Chaturvedi A; Lee DD; Md Sazzad H; von Holzen U; Zhang C; Schwarz RE; Awasthi N
    Cancer Biol Ther; 2021 Dec; 22(10-12):619-629. PubMed ID: 34882068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted dual inhibition of c-Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models.
    Grojean M; Schwarz MA; Schwarz JR; Hassan S; von Holzen U; Zhang C; Schwarz RE; Awasthi N
    J Cell Mol Med; 2021 Jun; 25(11):4950-4961. PubMed ID: 33939252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis.
    Newhook TE; Lindberg JM; Adair SJ; Kim AJ; Stelow EB; Rahma OE; Parsons JT; Bauer TW
    Ann Surg Oncol; 2016 Jun; 23(6):1993-2000. PubMed ID: 26847682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Orexin-A/OX1R System Induces Cell Death in Pancreatic Cancer Cells Resistant to Gemcitabine and Nab-Paclitaxel Treatment.
    Voisin T; Nicole P; Gratio V; Chassac A; Mansour D; Rebours V; Couvelard A; Couvineau A
    Front Oncol; 2022; 12():904327. PubMed ID: 35747788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
    Wen-Sheng W
    Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
    Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
    Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined PI3K and MAPK inhibition synergizes to suppress PDAC.
    Bye BA; Jack J; Pierce A; Walsh RM; Eades A; Chalise P; Olou A; VanSaun MN
    bioRxiv; 2023 Aug; ():. PubMed ID: 37645960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion: A case report in a patient with metastatic pancreatic adenocarcinoma.
    Neuzillet C; Babai S; Kempf E; Pujol G; Rousseau B; Le-Louët H; Christophe Tournigand
    Medicine (Baltimore); 2016 Jun; 95(26):e4006. PubMed ID: 27368013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model.
    Suenaga M; Yamada S; Fujii T; Tanaka C; Kanda M; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    J Surg Oncol; 2016 Mar; 113(4):413-9. PubMed ID: 27100026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
    Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
    Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heme Oxygenase-1 Inhibition Potentiates the Effects of Nab-Paclitaxel-Gemcitabine and Modulates the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma.
    Ahmad IM; Dafferner AJ; O'Connell KA; Mehla K; Britigan BE; Hollingsworth MA; Abdalla MY
    Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34066839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
    Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines.
    Ma Y; Schulz B; Trakooljul N; Al Ammar M; Sekora A; Sender S; Hadlich F; Zechner D; Weiss FU; Lerch MM; Jaster R; Junghanss C; Murua Escobar H
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.
    Cavalloni G; Peraldo-Neia C; Varamo C; Chiorino G; Sassi F; Aglietta M; Leone F
    Oncotarget; 2016 Aug; 7(32):52354-52363. PubMed ID: 27429047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
    Miller CR; Oliver KE; Farley JH
    Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.